One Nucleus Annual Review 2022

Providing Space for the Pioneers of Life Sciences As a world-leading developer, owner and operator of mission critical real estate solutions for the life sciences and technology industries, we’re proud to have a strong presence in both Cambridge, MA, and Cambridge, UK. In these vibrant ecosystems, the innovators and enterprising companies to whom we provide the necessary space to thrive, are in search of accelerating breakthroughs that seek to solve the biggest healthcare and bioscience challenges of our age. They need the right assortment of equipment, but also curated laboratory and office environments to succeed — and it is these ingredients which we offer to the hundreds of tenant partners across our trans-Atlantic portfolio.

Because innovation happens in proximity, not in isolation, life sciences hubs thrive by having access to a large talent pool, nearby academic and research institutions and close proximity to venture capital and other investors. The UK life sciences ecosystem not only has these key elements, but is also fueled by the growth in tenant demand underpinned by funding into the sector.

Of the 13.7 million square feet of research and workspace BioMed owns and operates in the UK and US, approximately one million square feet is in Cambridge, UK. This space is all fully leased, having recently welcomed two pioneering companies – Altos Labs and Bicycle Therapeutics – to our recently renovated Portway building at Granta Park, one of the largest purpose-built life sciences developments in the Oxford-Cambridge Arc and home to over 30 of the world’s largest life sciences companies and research organizations, including Pfizer, Illumina and Cancer Research UK. This represents a formidable cluster of collaboration and innovation that employs more than 3,700 people.

In addition to the 13.7 million square feet of operational space, BioMed maintains a premier development platform with 3.5 million square feet of Class A properties in active construction. To extend the runway of supply for the burgeoning life science sector globally, we’re also actively looking for ways to continue expanding this pipeline in all our key markets — including the UK — as represented by last year’s announcement that we intend to nearly double the size of our portfolio in Cambridge. Our best-in-class portfolio, market-leading platform and growing pipeline allows us to meet rapidly increasing demand in the UK. The UK life sciences industry is world-leading and life-saving, as the Oxford University and AstraZeneca COVID-19 vaccine demonstrated. The UK has consistently had strong government funding into the sector, with UK government spending on healthcare and R+D the highest in Europe and second in the world.

But it is not only the convergence of academic ties, government support and private investment that life sciences companies need. The pandemic has shown that some industries can operate successfully with remote workers, but essential lab work for drug discovery cannot be done from home. It requires highly specialized research and workspace. Having the right building in the right location is just as important as having the right talent.

Bill Kane, President - East Coast & UK Markets, BioMed Realty www.biomedrealty.com www.onenucleus.com | 37